Surufatinib Combination Trial for High-Risk Pancreatic Cancer Initiated
A trial is underway to evaluate surufatinib combined with gemcitabine and nab-paclitaxel in high-risk pancreatic cancer patients.
Asset / Drug
Drug and asset intelligence for Surufatinib with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
A randomized trial is underway to evaluate surufatinib as adjuvant therapy for pancreatic neuroendocrine tumors.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.